Product Name
CPT2, Polyclonal Antibody
Popular Item
Full Product Name
CPT2 Polyclonal Antibody
Product Synonym Names
CPT1; CPTASE; IIAE4
Product Gene Name
anti-CPT2 antibody
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P23786
Species Reactivity
Human, Mouse, Rat
Purity/Purification
Affinity Purification
Immunogen
Recombinant protein of human CPT2
Storage Buffer
PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
Preparation and Storage
Store at -20 degree C. Avoid freeze/thaw cycles.
Other Notes
Small volumes of anti-CPT2 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
anti-CPT2 antibody
The protein encoded by this gene is a nuclear protein which is transported to the mitochondrial inner membrane. Together with carnitine palmitoyltransferase I, the encoded protein oxidizes long-chain fatty acids in the mitochondria. Defects in this gene are associated with mitochondrial long-chain fatty-acid (LCFA) oxidation disorders.
Product Categories/Family for anti-CPT2 antibody
Primary antibody
Applications Tested/Suitable for anti-CPT2 antibody
Western Blot (WB)
Application Notes for anti-CPT2 antibody
WB: 1:500 - 2000
Western Blot (WB) of anti-CPT2 antibody
Western blot analysis of extracts of various cell lines, using CPT2 antibody at 1:1000 dilution.
Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (MBS128200) at 1:10000 dilution.
Lysates/proteins: 25ug per lane.
Blocking buffer: 3% nonfat dry milk in TBST.
Detection: ECL Basic Kit.
Exposure time: 1s.

NCBI/Uniprot data below describe general gene information for CPT2. It may not necessarily be applicable to this product.
NCBI Accession #
P23786.2
[Other Products]
UniProt Primary Accession #
P23786
[Other Products]
UniProt Secondary Accession #
Q5SW68; Q9BQ26; B2R6S0[Other Products]
UniProt Related Accession #
P23786[Other Products]
NCBI Official Full Name
Carnitine O-palmitoyltransferase 2, mitochondrial
NCBI Official Synonym Full Names
carnitine palmitoyltransferase 2
NCBI Official Symbol
CPT2 [Similar Products]
NCBI Official Synonym Symbols
CPT1; IIAE4; CPTASE
[Similar Products]
NCBI Protein Information
carnitine O-palmitoyltransferase 2, mitochondrial
UniProt Protein Name
Carnitine O-palmitoyltransferase 2, mitochondrial
UniProt Synonym Protein Names
Carnitine palmitoyltransferase II; CPT II
Protein Family
Carnitine O-palmitoyltransferase
UniProt Gene Name
CPT2 [Similar Products]
UniProt Synonym Gene Names
CPT1; CPT II [Similar Products]
NCBI Summary for CPT2
The protein encoded by this gene is a nuclear protein which is transported to the mitochondrial inner membrane. Together with carnitine palmitoyltransferase I, the encoded protein oxidizes long-chain fatty acids in the mitochondria. Defects in this gene are associated with mitochondrial long-chain fatty-acid (LCFA) oxidation disorders. [provided by RefSeq, Jul 2008]
UniProt Comments for CPT2
CPT2: Defects in CPT2 are the cause of carnitine palmitoyltransferase 2 deficiency late-onset (CPT2D); also known as CPT-II deficiency or CPT2 deficiency. CPT2D is an autosomal recessive disorder characterized by recurrent myoglobinuria, episodes of muscle pain, stiffness, and rhabdomyolysis. These symptoms are triggered by prolonged exercise, fasting or viral infection and patients are usually young *****s. In addition to this classical, late-onset, muscular type, a hepatic or hepatocardiomuscular form has been reported in infants. Clinical pictures in these children or neonates include hypoketotic hypoglycemia, liver dysfunction, cardiomyopathy and sudden death. Defects in CPT2 are the cause of carnitine palmitoyltransferase 2 deficiency infantile (CPT2DI). A disorder of mitochondrial long-chain fatty acid oxidation characterized by hepatic or hepato-cardio-muscular manifestations with onset in infancy. Clinical features include hypoketotic hypoglycemia, lethargy, seizures, hepatomegaly, liver dysfunction, cardiomegaly and dilated cardiomyopathy. Defects in CPT2 are the cause of carnitine palmitoyltransferase 2 deficiency lethal neonatal (CPT2D-LN); also known as lethal neonatal CPT-II deficiency. It is a lethal neonatal form of CPT2D. This rarely presentation is antenatal with cerebral periventricular cysts and cystic dysplastic kidneys. The clinical variability of the disease is likely attributed to the variable residual enzymatic activity. Defects in CPT2 are a cause of susceptibility to encephalopathy acute infection-induced type 4 (IIAE4). A severe neurologic complication of an infection. It manifests within days in otherwise healthy children after common viral infections, without evidence of viral infection of the brain or inflammatory cell infiltration. In affected children, high- grade fever is accompanied within 12 to 48 hours by febrile convulsions, often leading to coma, multiple-organ failure, brain edema, and high morbidity and mortality. The infections are usually viral, particularly influenza, although other viruses and even mycoplasma have been found to cause the disorder. Polymorphic variants in CPT2 can confer susceptibility to infection-induced encepalopathy. These variants do not cause classical carnitine palmitoyltransferase 2 deficiency, and patients harboring any of them are asymptomatic most of the time. However, they are prone to viral infection (high fever)-related encephalopathy (PubMed:21697855). Belongs to the carnitine/choline acetyltransferase family.
Protein type: EC 2.3.1.21; Lipid Metabolism - fatty acid; Mitochondrial; Transferase
Chromosomal Location of Human Ortholog: 1p32.3
Cellular Component: mitochondrial inner membrane; mitochondrion; nucleolus; nucleoplasm
Molecular Function: carnitine O-palmitoyltransferase activity
Biological Process: carnitine shuttle
Disease: Carnitine Palmitoyltransferase Ii Deficiency, Infantile; Carnitine Palmitoyltransferase Ii Deficiency, Late-onset; Carnitine Palmitoyltransferase Ii Deficiency, Lethal Neonatal; Encephalopathy, Acute, Infection-induced, Susceptibility To, 4
Research Articles on CPT2
1. The clinical presentation of patients with muscle carnitine palmitoyltransferase II deficiency is discussed in this review in line with enzymatic features. The thermolability of the mutant enzyme might explain why symptoms in muscle CPT II deficiency mainly occur during prolonged exercise, infections and exposure to cold. [review]
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.